Main | Meeting Information/Register | Faculty | Learning Objectives | CME | Disclosure                  For reference only; not available for CME credit Join us for a CME lecture and dinner meeting. Advances in SCLC: Challenging Patients, Difficult Decisions Patients with small cell lung cancer (SCLC) generally respond well to first-line therapy, but most relapse. For these patients, oncologists now have several treatment options, including traditional and new chemotherapeutic agents such as topoisomerase I inhibitors, semisynthetic vinca alkaloids, antimetabolites, and taxanes. Innovative dosing and administration strategies, along with novel combinations of these agents are improving outcomes for many patients with relapsed SCLC. If you have questions, please call 1-800-772-8277, ext. 164. Your call will be returned. Join our distinguished speaker as we focus on chemotherapeutic strategies to both improve tolerance and maximize efficacy in all patients, including those who are elderly or have poor performance status. We will also discuss various successful approaches to treating these patients and the application of these strategies in your practice.   Development Faculty John R. Eckardt, MD Director, Pharmaceutical Research The Center for Cancer Care & Research St. Louis, Missouri Mark R. Green, MD Gilbreth Professor of Clinical Oncology Medical University of South Carolina Charleston, South Carolina Joseph Treat, MD Vice Chairman, Department of Medical Oncology Professor of Medicine, Medical Director Fox Chase-Temple Cancer Center Philadelphia, PA Top TARGET AUDIENCE Oncologists who treat patients with small cell lung cancer. ACTIVITY GOAL To update oncologists on the most current, clinically relevant data on chemotherapeutic interventions for small cell lung cancer. LEARNING OBJECTIVES Evaluate traditional and novel treatment options for SCLC, including single and combination chemotherapies, and innovative dosing and administration strategies. Incorporate new approaches to improve tolerance to chemotherapy without reducing efficacy. Assess the safety and efficacy of traditional and novel chemotherapies in recurrent or refractory SCLC. Institute the most appropriate treatment regimens in order to optimize outcomes in patients with recurrent or refractory SCLC. Translate the latest data on safety and efficacy in special populations, especially the elderly and those with poor performance status, to optimize outcomes in these patients. Top Statement of Accreditation Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Projects In Knowledge designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. Top Disclosure Information The Disclosure Policy of Projects In Knowledge requires that faculty participating in a CME activity disclose to the audience: any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation; any relationship with the commercial supporter of this activity; whether any drugs or products under discussion are unapproved for use or investigational, ongoing research, or preliminary data. Faculty will disclose such discussion. For complete prescribing information on the products discussed during this CME activity, please see your current Physicians’ Desk Reference (PDR). John R. Eckardt, MD, has received grant/research support from, is a consultant for, and is on the speakers bureau of Aventis Pharmaceuticals, GlaxoSmithKline, Eli Lilly and Company, and Novartis Pharmaceuticals Corporation. Mark R. Green, MD, is a consultant for Novartis Pharmaceuticals Corporation. Joseph Treat, MD, is a consultant and stockholder for Neopharm Inc; and is on the speakers bureau of Amgen Inc, Aventis Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, and Eli Lilly and Company. The opinions expressed during this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge. This independent CME activity is planned and implemented in accordance with the ACCME Essential Areas and Policies. This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient. This independent CME activity is supported by an educational grant from GlaxoSmithKline. Top Recommend this to a colleague World Wide Web pages are copyrighted and may not be reproduced in any form without the express written consent of Projects In Knowledge, Inc.SM Copyright © 2004, Projects In Knowledge, Inc. All rights reserved. For questions or comments regarding this web site please contact: Webmaster